A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Inclusion Criteria: * Adequate complete blood counts, liver and renal function. * 12-lead electrocardiogram (ECG) within normal limits * Female subjects must be of non-childbearing potential; e.g. post-menopausal or pre-menopausal with surgical sterilization * Male subjects agree to use appropriate contraception * Willing to provide written informed consent and willing to comply with study requirements * Nonsmokers for at least 5 years before screening Exclusion Criteria: * Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk * Received an investigational agent within 90 days before the first dose of study drug or are in follow-up of another clinical study * Active serious mental illness or psychiatric disorder requiring current pharmacological intervention * History or evidence of alcohol or drug abuse within 12 months before screening. * History of intolerance to SC injection